Blog Posts
Read blog posts that discuss our company history, team members, and other industry-relevant topics.
From Bench to Bedside: Generalizable AI Model for ADC Biomarker Evaluation in NSCLC
This study demonstrates the potential of AI models to address key challenges in ADC biomarker evaluation for NSCLC. The strong alignment between our model predictions and pathologist assessments demonstrates the value of our automated scoring approach.
Meet Neelay Shah, Machine Learning Engineer on our Data Processing team!
Neelay and the Data Processing team develop pipelines to process data at scale for use-cases such as training foundation models. They ensure that data and models can be processed in a distributed fashion, efficiently spreading computational work across multiple machines to allow for scaling when large data sets are involved. They also partner closely with the Data Science team who use the infrastructure developed by the Machine Learning Engineers to perform experiments for client projects.
Meet Srishti Munjal Mehta, Scientific Program Manager on our Translational Programs team!
Srishti and the Translational Programs team work closely with clients on translational R&D projects including topics such as comprehensive tissue profiling and spatial analyses, precise quantification of challenging biomarkers, and prediction of biomarker expression.
Pathology's Evolution: How Aignostics Builds on Charité Berlin's 300-Year Legacy
Aignostics started in 2018 within the walls of the Berlin Institute of Health at Charité – Universitätsmedizin Berlin, before ultimately spinning-out in 2020. But did you know that Charité Berlin has a rich history dating all the way back to 1710? Let’s explore some of that history, along with the history of pathology’s digital transformation, to understand the origins and drivers of Aignostics’ founding.
Meet Timo Haschler, Senior Scientific Project Manager on our Target and Biomarker Discovery team!
Timo Haschler and his team work closely with clients to identify novel drug targets and biomarkers. This includes the multi-year collaboration we announced with Bayer in 2024, to identify novel cancer targets and co-create a target identification platform to enable better patient identification, stratification, and selection for clinical trials.
